Expert Review of Clinical Immunology

Papers
(The TQCC of Expert Review of Clinical Immunology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Natural history of COVID-19 and therapeutic options96
Diagnosis & management of alpha-gal syndrome: lessons from 2,500 patients87
Global systematic review of primary immunodeficiency registries76
A comparative review of immunoassays for COVID-19 detection72
Circulating Calprotectin as a Biomarker of COVID-19 Severity71
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis68
The role of IL-6 and IL-6 blockade in COVID-1961
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-1954
SARS-COV-2-related immune-inflammatory thyroid disorders: facts and perspectives52
Breast implant illness: scientific evidence of its existence50
Update on pollen-food allergy syndrome48
Systemic lupus erythematosus and risk of infection46
Early-life exposure to air pollution and childhood allergic diseases: an update on the link and its implications44
Atopic phenotypes and their implication in the atopic march34
Epidemiology of rheumatoid arthritis: genetic and environmental influences29
Ataxia-telangiectasia: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management29
The emerging role of type 2 inflammation in asthma28
Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis27
The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review27
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection26
Generalized pustular psoriasis: current management status and unmet medical needs in Japan25
New insights into the progression from cutaneous lupus to systemic lupus erythematosus24
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults24
Abrocitinib for the treatment of atopic dermatitis23
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation23
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials23
Mechanical ventilation in Guillain–Barré syndrome22
The infection risks of JAK inhibition22
Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives22
Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus22
Gut microbiota in Celiac Disease: microbes, metabolites, pathways and therapeutics21
Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion21
Emerging therapy options for IgG4-related disease20
Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis20
Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis20
Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events20
An update on VEXAS syndrome19
Calcipotriol/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data19
Is post-COVID syndrome an autoimmune disease?18
The pathogenic oral–gut–liver axis: new understandings and clinical implications18
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis18
Rheumatoid arthritis related interstitial lung disease18
Elimination diets for eosinophilic esophagitis: making the best choice17
Emerging therapies for ulcerative colitis17
Multimorbidity and comorbidity in psoriatic arthritis – a perspective17
A systematic review and meta-analysis of the association between the neutrophil, lymphocyte, and platelet count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio and COVID-19 progressi17
Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits17
Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology17
The role of PCSK9 in inflammation, immunity, and autoimmune diseases17
A 2020 update on the use of genetic testing for patients with primary immunodeficiency16
Impact of resolvin mediators in the immunopathology of diabetes and wound healing16
Therapeutic targeting of the IL-13 pathway in skin inflammation16
Clinical, immunological, and genetic features in 938 patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a systematic review16
An immunologist’s guide to immunosenescence and its treatment16
Autoimmune hemolytic anemia: causes and consequences15
Gut inflammation in CVID: causes and consequences15
The current status of biological treatment for uveitis15
HMGB1 in nasal inflammatory diseases: a reappraisal 30 years after its discovery14
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives14
Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic14
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis14
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment13
Comorbid allergic rhinitis and asthma: important clinical considerations13
Chimeric antigen receptor T-cell therapy for melanoma13
Glucocorticoids in rheumatoid arthritis still on first line: the reasons13
Biomarkers of chronic spontaneous urticaria and their clinical implications13
Tofacitinib for the treatment of active ankylosing spondylitis in adults13
Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis13
Machine learning approaches to improve disease management of patients with rheumatoid arthritis: review and future directions13
The clinical implications of the microbiome in the development of allergy diseases12
Gut immune homeostasis: the immunomodulatory role of Bacillus clausii, from basic to clinical evidence12
The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection11
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis11
Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS)11
A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transp11
Nanoparticle-based immunotherapy: state of the art and future perspectives11
Recent issues in JAK inhibitor safety: perspective for the clinician11
Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis11
Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives11
Dupilumab for the treatment of adolescents with atopic dermatitis11
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection11
Allergic contact dermatitis in children11
Convalescent plasma and hyperimmune globulin therapy in COVID-1911
Heterogeneity in myasthenia gravis: considerations for disease management11
Myosin light chain kinase regulates intestinal permeability of mucosal homeostasis in Crohn’s disease11
Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia11
An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications10
Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management10
Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-210
Autism spectrum disorders and natural killer cells: a review on pathogenesis and treatment10
New frontiers in precision medicine for Sjogren’s syndrome10
Diagnosis and management of hypersensitivity reactions to vaccines10
Biologics and atherosclerotic cardiovascular risk in rheumatoid arthritis: a review of evidence and mechanistic insights10
Current concepts underlying the pathophysiology of acute Charcot neuroarthropathy in the diabetic foot and ankle10
Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis10
Avacopan for the treatment of ANCA-associated vasculitis10
Clinical relevance of T follicular helper cells in systemic lupus erythematosus9
Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis9
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic9
Diagnosis and treatment of non-allergic rhinitis: focus on immunologic mechanisms9
Comparing available JAK inhibitors for treating patients with psoriasis9
A new case of congenital ficolin-3 deficiency with primary immunodeficiency9
Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review9
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab9
BRAF inhibitors and their immunological effects in malignant melanoma9
In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis9
Challenges in uncontrolled asthma in pediatrics: important considerations for the clinician9
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients9
Voclosporin: a novel calcineurin inhibitor for the management of lupus nephritis9
Ixekizumab for the treatment of ankylosing spondylitis9
Food allergy severity prediction: quite a way to go yet?8
Hematopoietic stem cell transplantation in systemic autoinflammatory diseases - the first one hundred transplanted patients8
Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia8
Recent insights into the pathogenesis of autoimmune hypophysitis8
Mast cell activation: beyond histamine and tryptase8
Model-based computational precision medicine to develop combination therapies for autoimmune diseases8
Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics8
Regulation of crystal induced inflammation: current understandings and clinical implications8
S. aureus and IgE-mediated diseases: pilot or copilot? A narrative review8
Current treatment options and long-term outcomes in patients with eosinophilic esophagitis8
Predicting lupus flares: epidemiological and disease related risk factors8
Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus8
Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency8
The effect of immunotherapy on cross-reactivity between house dust mite and other allergens in house dust mite -sensitized patients with allergic rhinitis8
Serum exosomal long noncoding RNA nuclear-enriched abundant transcript 1 predicts 90-day mortality in acute-on-chronic hepatitis B liver failure8
Oral immunotherapy for food allergy in children: is it worth it?8
Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets8
0.048454999923706